Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.38%
#2 Victoria VR Victoria VR +11.93%
#3 Movement Movement +11.39%
#4 Palladium Network Palladium Network +9.28%
#5 DMT-NAT DMT-NAT +6.25%
#6 Cryptopia Cryptopia +4.73%
#7 Pons Pons +4.23%
#8 GRVT Token GRVT Token +3.85%
#9 MarsCoin MarsCoin +3.69%
#10 COTI COTI +3.65%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Arch Therapeutics, Inc. Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

ARTH
Rangering i aksjer #42478
Arch Therapeutics, Inc., operating alongside its affiliated companies,... Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Aksjekurs
$0.0009
Sist synkronisert: 2025-05-27
Markedsverdi
$1.15K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Arch Therapeutics, Inc. (ARTH)

Kategori

Healthcare
Inntekter for Arch Therapeutics, Inc. (ARTH)
Inntekter i Jun 2024 TTM: $-12.26M
Ifølge Arch Therapeutics, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-12.26M. I 2022 hadde selskapet et resultat på $-5.28M, en økning sammenlignet med resultatet i 2021, som var $-6.24M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Arch Therapeutics, Inc. fra 2011 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-12.26M 75.61%
2023 $-6.98M 32.35%
2022 $-5.28M -15.46%
2021 $-6.24M 33.02%
2020 $-4.69M 3.16%
2019 $-4.55M -5.53%
2018 $-4.81M -38.19%
2017 $-7.79M 29.98%
2016 $-5.99M 103.30%
2015 $-2.95M -63.80%
2014 $-8.14M 339.25%
2013 $-1.85M 4,963.48%
2012 $-36.61K 626.84%
2011 $-5.04K 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -43,115.92%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -16,007.22%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -24,611.12%
BE